STOCK TITAN

InMed Pharmaceuticals (MTRI) SEC Filings

MTRI NASDAQ

Ticker history: INM became MTRI (Mentari Therapeutics, Inc.) on . Earlier news and filings retain their original names and dates. View INM history.

Rhea-AI Summary

InMed Pharmaceuticals Inc. (INM) is the issuer named in an amended Schedule 13G reporting that Squadron Master Fund LP, Squadron Capital Management LLC, Matthew Sesterhenn and William Blank each beneficially own 0 common shares, or 0% of the class. Each also reports zero sole and shared voting power and zero sole and shared dispositive power.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.83%
Tags
ownership
-
Rhea-AI Summary

InMed Pharmaceuticals Inc. (INM) completed its merger with Mentari Therapeutics on November 6, 2026, and changed its name to Mentari Therapeutics, Inc. Immediately before closing, Pre-Merger Mentari issued common shares and pre-funded warrants for approximately $490.0 million in gross proceeds, including approximately $52.7 million of convertible-note principal and accrued interest. Former Mentari securityholders held approximately 99.0% of the combined company on a fully diluted basis after closing, compared with approximately 1.0% for former InMed securityholders.

For the three months ended September 30, 2026, Pre-Merger Mentari reported a $32.2 million net loss, versus $6.6 million for the prior-year quarter, and had generated no revenue from product sales. Cash and cash equivalents were $45.8 million as of September 30, 2026. Management said cash and proceeds from the Merger and pre-closing financing were expected to fund operating plans for at least 12 months after the financial statements were issued.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.83%
Tags
current report
-
Rhea-AI Summary

InMed Pharmaceuticals Inc. (INM) is identified as issuer for this analysis, but the supplied Schedule 13G text identifies Mentari Therapeutics, Inc. as the issuer whose shares are reported. Commodore Capital LP, Commodore Capital Master LP, Michael Kramarz and Robert Egen Atkinson each report the same beneficial ownership position of 2,977,630 Mentari common shares, or 5.6%, as of November 6, 2026. The position carries shared voting and dispositive power; each filer reports zero sole voting and dispositive power. The percentage is based on 52,813,914 Mentari common shares reported issued and outstanding on that date.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.83%
Tags
ownership
Rhea-AI Summary

InMed Pharmaceuticals Inc. (INM) is identified as the issuer for Schedule 13G ownership disclosures by Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., Deep Track Special Opportunities Fund, LP, and David Kroin. Deep Track Capital and Kroin each reported beneficial ownership of 2,977,478 shares, or 5.64%; the Master Fund reported 2,214,135 shares (4.19%), and the Special Opportunities Fund reported 763,343 shares (1.45%). Each reported shared voting and dispositive power over its stated amount. The ownership amounts were reported as of November 13, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.83%
Tags
ownership
-
Rhea-AI Summary

After its merger-related name change to Mentari Therapeutics, Inc., InMed Pharmaceuticals Inc. had 52,813,914 common shares outstanding as of November 6, 2026; Fairmount Healthcare Fund II L.P. directly held 10,555,507 common shares, or 19.99%. Fairmount Funds Management LLC has shared voting and dispositive power over the shares; its managers, Peter Harwin and Tomas Kiselak, are also reporting persons and disclaim beneficial ownership except for Section 13(d) purposes.

Fund II also holds 4,013 Series A Preferred shares convertible into 4,013,000 common shares and pre-funded warrants for 1,468,222 common shares; these potential shares are excluded from the reported stake and subject to 19.99% beneficial ownership limits. The preferred-stock conversion limit automatically reduces to 9.99% when Fairmount and its affiliates beneficially own 9.0% or less. While at least 30% of the originally issued Series A Preferred Stock remains outstanding, holders may elect two directors, each entitled to three votes on matters presented to the board. Certain merger participants, including the reporting persons, agreed not to transfer covered securities until 180 days after the First Effective Time, subject to exceptions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.36%
Tags
ownership
-
Rhea-AI Summary

InMed Pharmaceuticals Inc. (INM) officer Jerad G. Seurer, General Counsel and Corporate Secretary, received an award of options covering 257,000 common shares on November 9, 2026, at a $16 per-share exercise price. The options vest 25% on November 9, 2027, then in equal monthly installments through November 9, 2030, subject to his continued service on each vesting date, and expire November 9, 2036.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.36%
Tags
insider
Rhea-AI Summary

InMed Pharmaceuticals Inc. director Laura Lee Sandler received a stock-option award on November 9, 2026, representing the right to purchase 37,000 common shares at an exercise price of $16 per share. The options vest in equal monthly installments through November 9, 2029, subject to her continued service on each vesting date.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.36%
Tags
insider
-
Rhea-AI Summary

InMed Pharmaceuticals Inc. reported that Senior Vice President, Finance and Chief Accounting Officer Brett R. Hagen received an award of options covering 171,000 common shares. The options vest 25% on November 9, 2027, with the remainder vesting in equal monthly installments through November 9, 2030, subject to his continued service on each vesting date.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.36%
Tags
insider
-
Rhea-AI Summary

InMed Pharmaceuticals Inc. (INM) reported that President and Chief Executive Officer Gregory J. Divis, who is also a director, received a stock-option award representing the right to purchase 1,560,599 common shares on November 9, 2026. The options vest 25% on November 9, 2027, then in equal monthly installments through November 9, 2030, subject to his continued service on each vesting date.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.36%
Tags
insider
Rhea-AI Summary

InMed Pharmaceuticals Inc. director Julianne Bruno was granted options covering 37,000 common shares on November 9, 2026, at an exercise price of $16 per share. The options vest in equal monthly installments through November 9, 2029, subject to her continued service on each vesting date, and expire November 9, 2036.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.36%
Tags
insider

FAQ

How many InMed Pharmaceuticals (MTRI) SEC filings are available on StockTitan?

StockTitan tracks 20 SEC filings for InMed Pharmaceuticals (MTRI). Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for InMed Pharmaceuticals (MTRI)?

The most recent SEC filing for InMed Pharmaceuticals (MTRI) was filed on November 16, 2026.